Italia markets close in 4 hours 55 minutes

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
271,91+2,98 (+1,11%)
Alla chiusura: 04:00PM EDT
272,66 +0,75 (+0,28%)
Dopo ore: 05:39PM EDT

Amgen Inc.

One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com

Settore/iHealthcare
SettoreDrug Manufacturers - General
Impiegati a tempo pieno26.700

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Robert A. BradwayChairman, CEO & President6,73MN/D1963
Mr. Peter H. GriffithExecutive VP & CFO3,07MN/D1959
Mr. Esteban SantosExecutive Vice President of Operations3,01MN/D1968
Dr. David M. Reese M.D.Executive VP & Chief Technology Officer3,4MN/D1963
Mr. Murdo GordonExecutive Vice President of Global Commercial Operations3,24MN/D1967
Mr. Matthew C. BuschChief Accounting Officer & VP of FinanceN/DN/D1974
Mr. Mike ZahigianSenior VP & Chief Information OfficerN/DN/DN/D
Dr. James E. Bradner M.D.Executive VP of Research and Development & Chief Scientific OfficerN/DN/D1972
Justin G. ClaeysVice President of Investor RelationsN/DN/DN/D
Mr. Jonathan P. GrahamExecutive VP, General Counsel & Secretary2,44MN/D1961
Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Governance aziendale

L'ISS Governance QualityScore di Amgen Inc. al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 8; diritti degli azionisti: 1; retribuzione: 2.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.